Cilapem is a broad-spectrum antibiotic generally used to help manage serious bacterial infections in many different parts of the body. It is applied in clinical settings to support management of complicated bacterial infections, including bacterial septicemia, complicated infections of the lower respiratory tract and intra-abdominal area, as well as deep-seated bone and joint and skin structure infections.

The medication is commonly used across conditions presenting with acute episodes where pathogens may be resistant to most common antibiotics. In these scenarios, the benefit provided helps ease the overall symptom burden during periods of heightened illness. It is applied across domains where additional symptomatic support is needed in critically ill patients facing challenging, resistant infectious processes.

Quick Fact: Support for Severe Systemic Symptoms

Cilapem is relevant when supportive symptom management is appropriate for the severe systemic inflammatory symptoms associated with conditions marked by increased physiological stress. It assists in managing symptoms that create noticeable physiological strain, such as high fever and rapid decline in a patient’s status, which contributes to maintaining functional stability during difficult episodes.

Regulatory References

1. NIH MedlinePlus overview of Imipenem and Cilastatin

Cilapem is an intravenous antibiotic combination of imipenem and cilastatin used to treat serious bacterial infections. Its use is determined by a patient's medical history and current health status.

---

Who Can Use Cilapem?

This medication is generally prescribed for patients with infections caused by susceptible bacteria, including complicated infections of the lower respiratory tract, urinary tract, skin and soft tissue, intra-abdominal area, and bone and joint infections. It may also be used for bacterial septicemia and endocarditis.

Who Cannot Use Cilapem (Contraindications)?

Cilapem is contraindicated in patients with a history of severe hypersensitivity or allergic reaction to imipenem, cilastatin, or any other component of the formulation. Due to the risk of cross-reactivity, patients with a known history of severe allergy to other beta-lactam antibiotics, such as penicillins or cephalosporins, should be treated with caution.

Special Precautions are Required in Patients With:	Rationale
Central Nervous System (CNS) Disorders	Increased risk of seizures or confusion.
Kidney Impairment	Dosage adjustments are essential to prevent accumulation and reduce CNS side effects.
Gastrointestinal Disease	Increased risk of Clostridioides difficile-associated diarrhea (CDAD).

It is crucial to inform a healthcare professional about all existing medical conditions and current medications, including valproic acid, as co-administration may reduce the therapeutic effect of the seizure medication.

Interactions with other medicines and products

The interaction profile for Cilapem (Imipenem and Cilastatin) documents a few clinically significant combinations where co-administration is generally restricted by regulatory authorities, largely due to effects on the central nervous system or drug elimination.

Key Interacting Medicines and Substances

Category	Specific Interacting Agent(s)	Primary Regulatory Restriction
Anticonvulsants	Valproic Acid, Divalproex Sodium	Concomitant use generally not recommended; risk of breakthrough seizures due to decreased anticonvulsant levels.
Antivirals	Ganciclovir	Co-administration is restricted; use only if the benefit outweighs the risk due to reports of generalized seizures.
Renal Excretion Inhibitors	Probenecid	Concomitant use is not recommended; Probenecid increases Imipenem plasma levels and half-life by decreasing its renal clearance.

Official Interaction-Context Constraints

The primary constraints documented in official labeling focus on maintaining therapeutic efficacy and avoiding serious adverse neurological events. The use with Valproic acid or Divalproex sodium is generally discouraged because the combination rapidly and significantly reduces the serum concentration of the anticonvulsant, which may result in loss of seizure control. The combination with Ganciclovir is associated with an increased risk of generalized seizures and is restricted unless necessary. Furthermore, co-administration with Probenecid is not recommended because it substantially alters the pharmacokinetics of Imipenem.

Irreversible Disruption of Bacterial Cell Wall Assembly

This domain covers the primary action of Imipenem, which covalently binds to and deactivates essential Penicillin-Binding Proteins (PBPs) within target bacteria. This targeted interference halts the crucial final step of peptidoglycan synthesis. This mechanistic sequence leads to the physiological consequence of bacterial cell lysis and death (a bactericidal effect).

Targeted Conservation of Active Drug Concentration

This domain focuses on the supporting role of Cilastatin, an inhibitor of the human enzyme Dehydropeptidase-I (DHP-I) in the kidney. By blocking this enzyme, Cilastatin prevents the premature breakdown of Imipenem, thereby modifying the systemic clearance of Imipenem, supporting a sustained, elevated concentration of the active component.

Pharmacokinetic-Pharmacodynamic Synergy

The drug operates via a synergistic dual-component mechanism where Imipenem provides the pharmacodynamic action (bacterial killing) and Cilastatin modulates the drug's metabolism and systemic stability. This combined action initiates and sustains a linked mechanistic cascade that leads to a sustained physiological reduction of the target bacterial population.

How Cilapem is Used: Official Administration Guidelines

Cilapem (Imipenem and Cilastatin) is a sterile powder preparation intended for Intravenous (IV) infusion in a supervised clinical setting. The dosage is determined by the imipenem component and is highly dependent on the patient's kidney function, with the total daily amount typically administered in equally divided doses.

---

Dosing and Administration Schedule

The medicine is administered on a fixed schedule, most commonly every 6 hours (q6h) or every 8 hours (q8h), to maintain a consistent concentration in the body. For adults with normal kidney function (creatinine clearance 90 mL/min), a common regimen is 500 mg every 6 hours or 1000 mg every 8 hours, with the maximum total daily dosage not exceeding 4 g.

Before administration, the powder must be reconstituted and diluted for IV infusion.

Administration Detail	Standard Instructions
IV Infusion Time	leq 500 mg doses are infused over 20 to 30 minutes; > 500 mg doses are infused over 40 to 60 minutes.
Course Duration	The length of treatment is variable and guided by the patient's condition, often lasting between 7 to 14 days.

---

Use in Specific Populations

Dose adjustment is required for adult patients with renal impairment (creatinine clearance < 90 mL/min), as the dose must be reduced and the interval adjusted based on the degree of kidney function. For patients undergoing hemodialysis, the medicine is to be administered immediately following the procedure.

In pediatric patients over three months of age, dosing is calculated based on body weight, typically 15 to 25 mg/kg administered every 6 hours.

Research evidence / Overview of studies for Cilapem

The research landscape for Cilapem (Imipenem/Cilastatin) consists primarily of Randomized Controlled Trials (RCTs) and systematic reviews that explored its application in severe bacterial infections. These studies focus on understanding how clinical conditions progress during acute, often life-threatening, episodes in hospital settings where the combination was applied. Findings describe group patterns and are used in the broader scientific assessment of the evidence, but research does not determine whether an individual will respond similarly.

---

Evidence for Use in Severe Systemic Infections (Septicemia and Critical Illness)

This medicine was evaluated in research exploring severe systemic infections, including bacterial septicemia (bloodstream infections) and other critical illnesses where the body is under severe physiological strain. Researchers utilized short-term RCTs, often comparing Cilapem to other broad-spectrum antibiotics, to monitor outcomes related to physical discomfort and systemic or functional imbalance. Research examined critical outcomes such as all-cause mortality (death) at specific time points and the overall clinical response (measurements of change in infection signs and symptoms).

---

Evidence for Use in Lower Respiratory Tract and Intra-abdominal Infections

Cilapem was evaluated in trials specifically addressing deep-seated infections, including complicated pneumonia (like hospital-acquired pneumonia) and complicated intra-abdominal infections (cIAI). The studies explored the application of this combination in patients with conditions characterized by acute or disruptive episodes. Researchers primarily monitored two key outcomes: the clinical status of the infection and the microbiological status (e.g., pathogen presence) at the infection site. The focus of this research is strictly on the acute-phase monitoring of the infection.

---

Documented Research Gaps and Uncertainties

The evidence base, while extensive for acute application, has documented limitations. A key limitation is that most research involves comparative studies against other antibiotics, rather than studies against a placebo. This structure limits the ability of the research to determine the absolute contribution of Cilapem versus other broad-spectrum therapies. Additionally, follow-up durations were limited, meaning that long-term effects regarding the sustainability of clinical findings are not fully established.

Key Studies & References

1. A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients
2. IMIPENEM AND CILASTATIN IMIPENEM AND CILASTATIN (Official US Prescribing Information / Label)

Common questions about Cilapem (FAQ)

Q: Does Cilapem change the way I feel generally?

Official product information indicates that side effects affecting the central nervous system (CNS) are reported with this medicine. These may include feelings of confusion, dizziness, tremors, and somnolence (sleepiness). These documented effects may affect your general sense of well-being while the medication is being administered.

Q: Are there any common side effects of Cilapem that are temporary?

Many common side effects, such as nausea, vomiting, and diarrhea, are reported in official labeling. Regulatory information suggests that these common effects may lessen or resolve gradually over time as the body adjusts to the medication.

Q: Can older people take Cilapem safely?

Official information indicates that no difference in side effects is anticipated for older people compared to younger adults. However, because kidney function often changes with age, official documents note that dosage adjustment based on kidney function is required.

Q: Does taking Cilapem long-term cause any different effects?

For patients who require long-term treatment with this medication, regulatory guidelines describe the need for regular monitoring of certain bodily functions. This includes checking liver function, kidney function, and blood values to observe for any changes over time.

Q: Can I drive or operate machinery while taking Cilapem?

Official product information advises caution regarding certain activities. Because this medication may cause central nervous system effects such as dizziness and somnolence (sleepiness), patients are advised to consider avoiding driving or operating machinery if they experience these effects.

Q: What is the difference between a common and a rare side effect of Cilapem?

Official documents classify side effects into frequency groups to describe their likelihood. Common side effects are generally those reported in 1% or more of patients in clinical trials. Less frequent occurrences fall into categories like less common or rare.

Q: How quickly should I expect to notice any effects from Cilapem?

Cilapem is an intravenous antibiotic designed to begin working rapidly in the body. The plasma half-life, which measures how quickly the medicine is cleared from the bloodstream, is approximately 1 hour in healthy individuals. The dosing schedule is set to maintain effective concentrations needed to fight the infection.

Q: Does Cilapem make you tired or sleepy?

Yes, regulatory labeling documents that somnolence (sleepiness) is a reported side effect affecting the central nervous system (CNS). Unusual tiredness or weakness has also been reported as a less common effect of the medication.

Q: How long does Cilapem stay in your system after you stop taking it?

In patients with normal kidney function, the plasma half-life (the time it takes for half of the drug to be eliminated) for the active components is approximately 1 hour. About 70% of the administered dose is typically recovered in the urine within 10 hours of administration.

Q: What kinds of food interactions does Cilapem have, if any?

The medicine does not have significant food-drug interactions listed in official documents, but the formulation does contain sodium. The sodium content is a factor to be considered for patients who are required to follow a controlled sodium diet, such as those with certain heart or blood pressure conditions.

Q: Is it safe to use Cilapem if I have a history of liver issues?

The labeling indicates that caution is warranted regarding use in patients with liver impairment or liver disease. Official warnings show that a dosage adjustment may be necessary, and regular monitoring of liver function may be required if the medication is taken long-term.

Q: Is it common to have headaches when first starting Cilapem?

Headaches are not typically listed among the common side effects that occur in 1% or more of patients in the official safety tables. While they may be reported, they fall into the categories of less frequent occurrences.

Q: Does Cilapem interact with alcohol?

Regulatory sources describe alcohol as a substance that may interact with the medicine. This combination may cause or increase central nervous system effects, specifically increasing feelings of dizziness and sleepiness.

Q: Can Cilapem affect my blood pressure?

Yes, hypotension (low blood pressure) is a documented cardiovascular side effect of the medicine. Additionally, the sodium content in the medication is a factor to be considered for patients with pre-existing high blood pressure.

Q: Is it true that Cilapem can affect sleep patterns?

Official information notes that somnolence (sleepiness) is a side effect affecting the central nervous system (CNS). This documented effect on alertness may indirectly influence a patient's normal sleep-wake cycle.

How to Store and Dispose of Cilapem

Cilapem (Imipenem and Cilastatin for Injection, USP) must be stored and handled according to regulatory requirements to maintain its stability.

Storage Requirements

The unreconstituted powder must be stored at controlled room temperature, which is defined as 20°C to 25°C (68°F to 77°F). The powder requires protection from excessive moisture and light. The medicine must be kept out of the reach of children.

Product Form	Storage Temperature	Maximum Stability Time
Unreconstituted Powder	20°C to 25°C	Until Expiration Date
Reconstituted Solution	20°C to 25°C	4 hours
Reconstituted Solution	4°C (Refrigerated)	24 hours

Disposal Instructions

Unused or expired Cilapem must be disposed of according to local regulations to ensure proper pharmaceutical waste handling.